Elanco U.S. Inc., a subsidiary of Eli Lilly and Company, will acquire Boehringer Ingelheim Vetmedica Inc.'s U.S. feline, canine and rabies vaccines portfolio - as well as a manufacturing and R&D site - for $885 million. The deal will diversify Elanco's U.S. companion animal portfolio by complementing its offerings for dogs and cats.
Joining Elanco's U.S. portfolio - which currently includes parasiticides, pain and dermatology medicines - will be routinely administered vaccines for bordetella, Lyme disease, rabies and parvovirus, among others. Also included in the agreement are several pipeline assets.
The Fort Dodge, Iowa-based facility brings capacity to manufacture the acquired products as well as R&D and testing capabilities, including an on-site veterinary research center and lab space.
"We understand the unique bond that owners share with pets and are committed to helping those pets live longer, healthier lives," said Jeff Simmons, president, Elanco Animal Health. "With a growing portfolio addressing both prevention and treatment of disease, Elanco can partner with veterinarians and pet caregivers to do just that."
The acquisition is anticipated to close by early 2017, subject to approval by the Federal Trade Commission and also subject to antitrust approval and closing of Boehringer Ingelheim's asset swap transaction with Sanofi.